U.S. Markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8800+0.0800 (+2.86%)
At close: 4:00PM EDT

2.9000 +0.02 (0.69%)
After hours: 5:43PM EDT

Sign in to post a message.
  • A
    Ash
    My 2 cents :

    The price drop may be a reaction to their presentation comment that they may issue more shares or debt in the future (didn't specify which) - but a fear of dilution. However, they have enough liquidity that they do not need cash through end of 2021.

    On the positive side, their marketing and sales strategy was well thought out and they seem to be doing well in that regard. Note that this is a big deal drug - large market, lots of competitors, educating on the brand and the benefits/ease of the new way of using it. Also, the production process seems to be going well too.

    This takes time, folks. I liked their presentation as they have a solid plan that they are executing upon.
  • D
    D
    Buy the rumor sell the news is for short term traders. You invest longterm in good companies.
    Bullish
  • m
    mario
    what is going on with this stock
  • J
    Julien
    Going back to 2.80 soon maybe ... they need to sell their product - retail contract etc.
  • M
    Mario
    hope most of you are following me on stocktwits. my current position is 850,000 shares average of 2.60 so my conviction level is at it's highest as we approach launch and a series of catalysts. below is my latest from stocktwits. i can sense a breakout is imminent. good luck everyone..
    --------------------------------------------------------------------------------------
    Why I would buy Agile for $10 if I was a big pharma CEO

    It’s all about the money!
    Nothing else matters!
    The investment MUST make sense!
    This one makes perfect sense!

    At a cost of $870m the financial risk would be minimal - 3 year break even point assuming worse case scenario of a conservative revenue projection similar to Xulane (inferior patch) & also assuming revenues remained flat as a pancake over the 3 year duration. A more likely scenario is revenues approaching $600m (15% of market share) by year 3 so break even is about 2 years. A CEO’s strategy & vision outlook is always 5+ years so this acquisition exceeds expectations.

    do not let share price fool you about company’s worth. most of time there is a huge disconnect between those two especially in micro cap biotechs prior to significant events due to institutional manipulation. pay attention to insider activity - are they buying or selling.

    I am not saying a buyout will occur but am saying - “it just makes sense”
  • U
    Ungsang
    There is a solid reason why I believe this stock will rise sky high(above 10). The patch already received an FDA approval and it demonstrates significantly low side-effects compared to Xulane(which is a single competitor in the market). So there's no risk involved in FDA approval, unlike other bio stocks. and we have already confirmed that there is a significant demand for a "safe" and "effective" contraceptive patch. The addressable market is just enormous. This is a safe ride and we'll see 10 before the end of this year
  • R
    Richard
    @Mario. Please stay off this board. After another one of your long winded theories, Stock is down 20%. I don’t know who is worse, you or Al.
  • B
    Bill
    Almost every single biotech has gotten HAMMERED today.
  • l
    luke
    Richard is playing long when in fact he is a short... Always complaining about the company and advising others to go invest in something other than AGRX.
  • J
    John
    Happy for this move today for us longs but I always get a little nervous and suspicious of these 'random' big spikes when there's no news. We've all been blindsided before. Particularly when another exciting newbie contraceptive stock, EVFM, has been extremely weak lately, down another 6% today. The extreme divergence of these similar stocks 2 makes no sense.
  • D
    David
    I am new to this stock but I like what I've researched and read on the company...dipping the toe in with 130 shares at $3.70
  • S
    SteveM
    there is nothing wrong with this product - this is a power grab to get shares before the next increase...I'm holding...
  • m
    martin
    Two Huge funds have stock in AGRX. Black Rock and State Street. I follow there lead.
  • W
    Wayne
    So far a total of 5 (ARIA, ARRY, ACHN, JUNO & IMMU) got taken out from my portfolio, I believe this will be next, load it up!
    Bullish
  • R
    Richard
    Anyone see the chat? Investors don’t seem overly excited
  • c
    carol
    Wow, big jump today. I am happy to see it, but am not sure why it is happening today.
  • N
    Nathan
    September 15th - two talks at women’s healthcare innovation summit
    September 16th - HC Wainwright investment conference
    September 21st - investor/analyst day

    it’s coming soon
    Bullish
  • m
    mizan
    Time to buy AGRX. Lots of positive news after upcoming launch of the patch.
  • S
    SteveM
    same typical pattern -
  • R
    Richard
    Fireside chat seemed more like a fizzle than a fire. Can this team really deliver? Hopeful they just sell to big Pharma so we can make some $$$. Tired of expensive plans that don’t pay off.